BHVN rises on SK Biopharmaceuticals epilepsy drug license
BHVN is trading higher following SK Biopharmaceuticals’ license for an epilepsy drug, with retail now awaiting an obesity trial readout.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.